8 March 2018
EMA/PRAC/135878/2018

# PRAC List of questions

To be addressed by the marketing authorisation holder

Article 20 of Regulation (EC) No 726/2004 resulting from pharmacovigilance data

Procedure number: EMEA/H/A-20/1462/C/00/3862/0018

Invented name: Zinbryta

INN/active substance: daclizumab beta

Marketing authorisation holder: Biogen Idec Ltd

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
**Telephone** +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
**Send a question via our website** www.ema.europa.eu/contact

# Questions

The marketing authorisation holder (MAH) is requested to address the following questions:

Question 1

The MAH should provide information on the use of daclizumab beta regarding the estimated patient exposure to daclizumab beta in the different European Union (EU) Member States (MSs). This should include data from completed and ongoing clinical studies and all post-marketing sources (number and patients-years of treatment).

Question 2

The MAH should provide detailed information on all cases (narrative and tabulated format) of central nervous system (CNS) adverse drug reactions, including cases from MAH-sponsored and non-MAH sponsored studies, spontaneous reports and literature. This should include a description of the cases, time to onset (and time since last dose), number of doses received, management and outcome (including time to resolution when relevant), results of brain biopsies and laboratory findings, patient characteristics, risk factors, concomitant medications and actions taken to manage the adverse drug reactions (ADRs). Cases of lack of efficacy should also be included together with an evaluation to conclude whether these cases are related to autoimmune-encephalitis. Based on this analysis, cases suggestive of encephalitis/meningoencephalitis should be identified and an estimation on the magnitude of the risk should be provided.

Question 3

The MAH should also provide a comprehensive cumulative review of cases likely to be related to immune-mediated adverse reactions from studies, spontaneous reports and literature, discussing the biological plausibility based on the known mechanism of action of the product.

Question 4

The MAH is asked to discuss the potential pathophysiological mechanism of immune-mediated reactions associated with daclizumab beta.

Question 5

The MAH should provide a comprehensive assessment of the current benefit-risk of the product taking into account all available data.